|
|
Immunovant Inc (NASDAQ: IMVT) |
|
Price: $23.0500
$-0.35 
-1.496%
|
| Day's High:
| $23.57
| Week Perf:
| -3.39 %
|
| Day's Low: |
$ 23.03 |
30 Day Perf: |
-10.87 % |
| Volume (M): |
1,193 |
52 Wk High: |
$ 39.55 |
| Volume (M$): |
$ 27,492 |
52 Wk Avg: |
$29.52 |
| Open: |
$23.38 |
52 Wk Low: |
$22.41 |
|
|
| Market Capitalization (Millions $) |
3,376 |
| Shares
Outstanding (Millions) |
146 |
| Employees |
146 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-323 |
| Cash Flow (TTM) (Millions $) |
203 |
| Capital Exp. (TTM) (Millions $) |
1 |
Immunovant Inc
Immunovant Inc is a biopharmaceutical company that focuses on developing novel therapies for autoimmune diseases. The company utilizes a proprietary technology platform to develop small molecules and monoclonal antibodies that target specific components of the immune system to modulate immune responses.
Immunovant's lead candidate, IMVT-1401, is an investigational anti-FcRn antibody being developed for the treatment of autoimmune diseases, including myasthenia gravis and pemphigus vulgaris. FcRn is a protein that plays a role in the recycling of immunoglobulins, and by inhibiting its function, IMVT-1401 aims to reduce the levels of pathogenic antibodies that contribute to autoimmune disease.
The company's research and development efforts are driven by a team of experienced scientists and clinicians with expertise in immunology and autoimmune diseases. Immunovant is committed to advancing its pipeline of innovative therapies to address the unmet medical needs of patients with autoimmune disorders.
Immunovant Inc was previously a subsidiary of Roivant Sciences but became an independent publicly traded company in October 2019. The company is headquartered in New York, United States.
Company Address: 320 West 37th Street New York, 10018 NY
Company Phone Number: 580-3099 Stock Exchange / Ticker: NASDAQ IMVT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Immunovant Inc
In its recent financial report for the fourth quarter and fiscal year ended March 31, 2024, Immunovant, Inc. (Nasdaq: IMVT) has announced an increase in its loss per share compared to the previous year. For the fourth quarter of 2024, the company reported a loss per share of $-0.46, compared to $-0.41 a year ago. This represents a widening of the loss from the previous reporting period, where it was $-0.36 per share.
However, the company's revenue remained unchanged at $0.00 million from $4.10 million in the corresponding reporting period a year ago, as well as sequentially. Immunovant Inc realized a net loss of $-75.319 million for the fourth quarter of 2024, which is larger than the net loss of $-59.432 million reported a year ago.
In the financial 12 Months 2024, Immunovant Inc announced a loss of $-259.34 million and revenue of $0.00 million. The net loss per share has widened to $-1.88 from $-1.71 in the previous financial year, but the revenue remained unchanged at $0.00 million from a year ago.
|
| Clinical Study
Published Wed, May 29 2024 8:01 PM UTC
Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company that strives to improve the lives of individuals suffering from autoimmune diseases. In their recent corporate updates and financial results for the fourth quarter and fiscal year ended March 31, 2024, Immunovant highlighted their commitment to revolutionizing the treatment landscape through their novel d...
|
| Immunovant Inc
Immunovant Inc, a clinical-stage immunology company focused on autoimmune diseases, has reported improved financial results for the three months ending December 31, 2023. The company's loss per share decreased to $-0.36 per share, compared to $-0.49 per share in the same period the previous year. This represents an improvement in earnings compared to the preceding financial reporting period, where the company realized $-0.45 per share.
During the October to December 2023 timeframe, Immunovant Inc reported a net loss of $-51.418 million, which is a reduction from the $-63.227 million loss in the comparable financial reporting period a year ago. This indicates a positive trend in the company's financial performance.
|
| Clinical Study
Published Wed, Dec 20 2023 9:30 PM UTC
NEW YORK, Dec. 20, 2023 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company committed to enhancing the quality of life for individuals with autoimmune diseases, has made a groundbreaking breakthrough with its drug, batoclimab. The initial data from a 24-week Phase 2 clinical trial has unveiled extraordinary results, showcasing response rates surpassing 50%...
|
| Clinical Study
Published Tue, Nov 28 2023 12:00 PM UTC
Immunovant s IMVT-1402 Demonstrates Promising Results as a Best-in-Class FcRn Inhibitor
NEW YORK, Nov. 28, 2023 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company committed to improving the lives of individuals with autoimmune diseases, has announced positive early findings from the Phase 1 clinical trial of IMVT-1402. These initial results from the 6...
|
| Per Share |
Current |
| Earnings (TTM) |
-2.16 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
1.39 $ |
| Cash |
3.23 $
|
| Book Value |
3.07 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.16 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
1.39 $ |
| Cash |
3.23 $
|
| Book Value |
3.07 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
